9052 Background: Until recently, the standard treatment for advanced malignant pleural
mesothelioma (MPM) was only cisplatin plus pemetrexed. Nivolumab, an anti-programmed …

Background There is an increasing interest in the use of IO therapy in Mesothelioma (MPM).
We previously reported on the effect of nivolumab (sa) in patients with recurrent MPM with a …

The management of pleural mesothelioma has changed with the demonstration that first-line
checkpoint blockade therapy improves survival. This review covers issues of relevance to …

Objective: Rare disease Background: Malignant pleural mesothelioma (MPM) is a highly
lethal cancer with a median survival of∼ 12 months even with aggressive intervention …

Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from
pleural mesothelial cells, which is associated with dismal prognostic outcome. According to …

Background: Pleural mesothelioma is a rare cancer with a dismal prognosis and few
therapeutic options, especially in the pretreated setting. Immunotherapy with checkpoint …

Background Malignant pleural mesothelioma (MPM) is a cancer with a high mortality rate
and few therapeutic options. After platinum–pemetrexed combination, no further promising …

Objectives: Results for malignant pleural mesothelioma (MPM) patients following first-line
treatment with nivolumab plus ipilimumab obtained with immunotherapy-modified PERCIST …

Background There is a strong unmet need to improve systemic therapy in mesothelioma.
Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural …

Malignant pleural mesothelioma (MPM) is a tumor with a poor prognosis, whose incidence is
increasing worldwide due to widespread previous exposure to asbestos. Only few patients …